隈部 篤寛 (クマベ アツヒロ)

Kumabe, Atsuhiro

写真a

所属(所属キャンパス)

医学部 放射線科学教室(治療) (信濃町)

職名

助教(有期)

学歴 【 表示 / 非表示

  • 1999年04月
    -
    2005年03月

    慶應義塾, 医学部

    大学, 卒業

  • 2012年04月
    -
    2016年03月

    慶應義塾, 医学研究科

    大学院, 修了, 博士

学位 【 表示 / 非表示

  • 博士(医学), 慶應義塾, 課程, 2016年04月

免許・資格 【 表示 / 非表示

  • 日本医学放射線学会放射線治療専門医, 2012年09月

  • がん治療認定医, 2017年04月

 

研究分野 【 表示 / 非表示

  • 放射線科学

 

論文 【 表示 / 非表示

  • Long-term results of concurrent chemoradiotherapy with daily-low-dose continuous infusion of 5-fluorouracil and cisplatin (LDFP) for Stage I-II esophageal carcinoma

    Kumabe A., Fukada J., Kota R., Koike N., Shiraishi Y., Seki S., Yoshida K., Kitagawa Y., Shigematsu N.

    Diseases of the Esophagus (Diseases of the Esophagus)  31 ( 4 )  2018年04月

    ISSN  11208694

     概要を見る

    © The Author(s) 2017. Published by Oxford University Press on behalf of International Society for Diseases of the Esophagus. All rights reserved. We investigated long-term treatment outcomes and the feasibility of chemoradiotherapy consisting of daily-low-dose 5-fluorouracil and cisplatin (LDFP) chemotherapy plus radiotherapy for Stage I-II squamous cell esophageal cancer. Treatment records from the 2000 through 2008 period were reviewed retrospectively. Fractionated radiotherapy was performed with a total dose of 60 Gy delivered in 2 Gy per fraction. LDFP chemotherapy, as continuous infusion of 200 mg/m 2 5-fluorouracil combined with one hour infusion of 4 mg/m 2 cisplatin, was administered on the same days as radiotherapy. Survival was calculated by the Kaplan-Meier method. Survival, responses, failure patterns, and toxicities were evaluated. Seventy-six (47 stage I and 29 stage II) patients were analyzed with a median follow-up of 93.6 months. The 8-year overall survival (OS), progression-free survival (PFS) and cause-specific survival (CSS) rates were 63.4%, 49.8%, and 76.7%, respectively. The 8-year OS, PFS, and CSS for stage I and stage II patients were 71.0%/56.1%/82.9% and 45.2%/40.2%/66.6%, respectively. Sixty-eight patients (89.5%) completed the treatment regimen. A complete response (CR) was achieved in 68 patients (89.5%). Twenty-five patients (36.8%) experienced recurrence after CR. The failure patterns were (overlap included): local failure (n = 12), nodal metastasis (n = 12), distant metastasis (n = 3), details unknown (n = 2). Salvage therapy was performed for local failure; endoscopic therapy (n = 7) or surgery (n = 2). Six patients remain alive without relapse after salvage endoscopic therapy. Major Grade 3 or higher acute adverse events were leukopenia (22%), anorexia (17%), and esophagitis (11%). Major late toxicities (Grade 3 or 4) involved pericardial effusion (12%), pleural effusion (4%), and esophageal stenosis (3%). Chemoradiotherapy with LDFP provided favorable long-term survival with acceptable toxicity for Stage I-II squamous cell esophageal cancer. The tumor response was excellent, but close endoscopic follow-up is essential for detecting and treating local recurrence.

  • Long-term Clinical Results of Concurrent Chemoradiotherapy for Patients with Cervical Esophageal Squamous Cell Carcinoma.

    Kumabe A, Zenda S, Motegi A et al.

    37 ( 9 ) 5039 - 5044 2017年09月

    研究論文(学術雑誌), 単著, 査読有り

  • Three-dimensional conformal arc radiotherapy using a C-arm linear accelerator with a computed tomography on-rail system for prostate cancer: clinical outcomes.

    Kumabe A, Fukuhara N, Utsunomiya T et al.

    Radiation Oncology 10 ( 28 )  2015年10月

    研究論文(学術雑誌), 査読有り

競争的資金等の研究課題 【 表示 / 非表示

  • 早期非小細胞肺癌に対する、新規PET薬剤を用いた定位放射線治療の最適化の研究

    2018年04月
    -
    2020年03月

    文部科学省・日本学術振興会, 科学研究費助成事業, 隈部 篤寛, 若手研究, 補助金,  代表

 

担当授業科目 【 表示 / 非表示

  • 放射線医学講義

    2019年度